CEACAM5 and neutropenia: Studies of the real-world use of FTD/TPI have suggested that carcinoembryonic antigen (CEA) < 200, neutrophil-to-lymphocyte ratio (NLR) < 5 and the development of grade 3 neutropenia may predict a favourable efficacy of FTD/TPI [8], while the number of previous lines of therapy was prognostic for OS and PFS in other studies [9].